Latest News & Features
Big Pharma
The Warner-Lambert v Actavis case concerning second medical use patents has resulted in a carefully considered judgment and there are some clear lessons to be learnt, says Arty Rajendra of Rouse Legal. 1 October 2015
Africa
The international police organisation Interpol plays a vital role in connecting law enforcement and health authorities around the world in the fight against pharmaceutical crime. Aline Plançon reports. 1 October 2015
Big Pharma
An advocate-general at Europe’s highest court has said SPCs should come into effect once an applicant for a marketing authorisation has been notified of that authorisation. This is good news for SPC owners, say Anja Lunze and Paul England of Taylor Wessing. 24 September 2015
Americas
Researchers should keep in mind that broad claims applying the discovery of a biomarker and disease correlation are currently patentable in Europe but not in the US. Andrew Carridge and Neil Thornton of Reddie & Grose report. 17 September 2015
Americas
Many players are piling into the scrum surrounding the patent eligibility of CRISPR technology. Mercedes Meyer of Drinker Biddle & Reath discusses the legal implications of CRISPR as a potential groundbreaking foundation technology. 17 September 2015
Big Pharma
Aldgate Tower will make an ideal home for the UK division of the UPC, with many advantages for its likely users, says Claire Phipps-Jones of Bristows. 10 September 2015
Americas
Congress has apparently taken note of the strategy of hedge fund manager Kyle Bass to take advantage of the IPR process, with two pending patent reform bills which include provisions that could curtail his activities, says John Abramic of Steptoe & Johnson. 3 September 2015
Big Pharma
The competence in various areas of the new Unified Patent Court is a matter of conjecture, as Paul England and Christof Höhne of law firm Taylor Wessing report. 27 August 2015
Americas
A recent decision in Canada means defendants in patent infringement cases can raise the non-infringing alternative defence in response to damages claims. Mark Biernacki and Cameron Weir of Smart & Biggar/Fetherstonhaugh considers its potential impact on litigation between drugs companies. 20 August 2015
article
US Congress must exempt biopharmaceutical patents from PTAB review to ensure continued medical innovation, argues Peter Pitts of the Center for Medicine in the Public Interest. 13 August 2015